EClinicalMedicine · 2024 · 14 citations · 18 references
MedicineOncologySurgeryNeuro-oncologySurgical OncologySurvival AnalysisBrain TumorsCancer Survival AnalysisMalignant NeoplasmsMolecular Classification Of TumorsPediatric Brain TumorsPediatric Surgical OncologyClinical Significance AssessmentDisease RiskHigh-risk Feature AssessmentMedulloblastoma PathologyPediatric Brain Tumor SurgeryUnivariate Analysis
Background: primary tumour residuum post-surgery) typically receive intensified treatment. However, the association of STR with poor outcomes has not been observed consistently, questioning the validity of STR as a high-risk disease feature. Methods: We collected extent of resection (EOR) data from 1110 patients (from UK CCLG centres (n = 416, collected between September 1990 and July 2014) and published (n = 694) cohorts), the largest cohort of molecularly and clinically annotated tumours assembled to specifically assess the significance of EOR. We performed association and univariable/multivariable survival analyses, assessing overall survival (OS) cohort-wide and with reference to the four consensus medulloblastoma molecular groups and clinical features. Findings: STR was reported in 20% (226/1110) of patients. Non-WNT (p = 0.047), children <5 years at diagnosis (p = 0.021) and metastatic patients (p < 0.0001) were significantly more likely to have a STR. In cohort-wide analysis, STR was associated with worse survival in univariable analysis (p < 0.0001). Examination of specific disease contexts showed that STR was prognostic in univariate analysis for patients receiving cranio-spinal irradiation (CSI) and chemotherapy (p = 0.016) and for patients with Group 3 tumours receiving CSI (p = 0.039). STR was not independently prognostic in multivariable analyses; outcomes for patients who have STR as their only risk-feature are as per standard-risk disease. Specifically, STR was not prognostic in non-metastatic patients that received upfront CSI. Interpretation: resection can continue to be carried out for patients with medulloblastoma and suggest STR should not inform patient management when observed as a sole, isolated risk-feature. Funding: Cancer Research UK, Newcastle Hospitals Charity, Children's Cancer North, British Division of the International Academy of Pathology.
18
Molecular subgroups of medulloblastoma: the current consensus
Michael D. Taylor, Paul A. Northcott, Andrey Korshunov et al. · Acta Neuropathologica · 2011 · 2K citations · Full text
Paul M. Zeltzer, James M. Boyett, Jonathan L. Finlay et al. · Journal of Clinical Oncology · 1999 · 756 citations
Medicine, Oncology, Pediatrics +17